RegenX Science

What RegenX Science does

RegenX Science is a clinical-stage regenerative medicine biotechnology company developing a proprietary extracellular matrix (ECM) biomaterial technology derived from urodele (salamander/axolotl) tissue. Founded in 2016 and headquartered in West Palm Beach, Florida, the company leverages Type XII collagen — a protein central to the salamander's regenerative capacity — to create scaffolds that promote tissue regeneration while exhibiting bacteriostatic, anti-viral, and anti-inflammatory properties. The intended clinical applications include wound healing, burn recovery, and tissue repair, with future potential in hair regrowth via regeneration of skin and underlying structures. End customers are expected to be dermatologists, clinical specialists, and healthcare institutions.

The company operates a translational science platform that has progressed through proteomics, in vitro genomics, in vivo porcine wound-healing studies, and safety/toxicology assessments, and is now advancing through human clinical trials. Multiple products are in various stages of development, with patents filed and pending in the USA and internationally. A Scientific Advisory Board comprising board-certified dermatologists, facial plastic surgeons, and pharmaceutical formulators with deep commercialization track records supports clinical translation and commercial strategy.

RegenX is pre-revenue and has not yet obtained regulatory approval or launched commercial products. The company funds operations through securities offerings, having raised $5 million of a $7 million SEC-registered offering (Form D filed September 2022). The intended go-to-market upon commercialization is direct sales to clinical and healthcare provider accounts, leveraging the advisory board's clinical relationships. Distribution is being prepared for a global clinical/healthcare provider channel, though specific pricing models, distribution partners, and commercial launch timelines remain undisclosed.

Name

RegenX Science

Legal name

RegenX Science Inc.

Website

https://regenxscience.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

RegenX Science is a clinical-stage regenerative medicine biotech developing a proprietary urodele (salamander/axolotl)-derived extracellular matrix biomaterial leveraging Type XII collagen for wound healing, burn recovery, and tissue repair applications targeting dermatologists and clinical healthcare providers.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biomaterials

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAGAG

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAAGAB

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAAGAL

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

• Regenerative biomaterials
• Wound healing technology
• Tissue regeneration products
• Extracellular matrix scaffolds
• Regenerative medicine therapeutics

Headquarters

HQ city

West Palm Beach

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

RegenX Science develops a proprietary extracellular matrix (ECM)-based regenerative biomaterial inspired by urodele (salamander/axolotl) tissue and utilizing Type XII collagen. The biomaterial functions as a bioactive scaffold for wound healing, burn recovery, and tissue repair applications, providing bacteriostatic, anti-viral, and anti-inflammatory properties to accelerate tissue regeneration while minimizing scarring. Products are currently advancing through clinical trials toward regulatory approval.

Product overview

RegenX Science offers a single unified product: a proprietary extracellular matrix (ECM)-based regenerative biomaterial technology. This biomaterial serves as the core platform for all wound healing, burn recovery, and tissue repair applications. The technology is inspired by nature's most remarkable healing organisms (such as salamanders) and creates an optimal environment for tissue regrowth through a scaffold mechanism. The company is currently advancing through clinical trials to demonstrate safety and efficacy in human patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Proprietary Regenerative Biomaterial (Urodele ECM Scaffold) A proprietary extracellular matrix (ECM)-based biomaterial inspired by regenerative organisms such as salamanders/axolotls, utilizing Type XII urodele collagen. The biomaterial serves as a scaffold for tissue regrowth and is bacteriostatic, anti-viral, and anti-inflammatory, promoting safe and effective wound healing, burn recovery, and tissue repair with minimal scarring. It is intended for clinical use by dermatologists, wound care specialists, and other healthcare providers treating damaged skin and open wounds.

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• MiMedx Group: Commercial-stage regenerative medicine company selling placental tissue-based skin substitutes and wound-care biologics. Directly comparable to RegenX as a biologic skin-substitute developer targeting wound healing, with the same regulatory pathway (HCT/P and biologic product approvals).
• Organogenesis Holdings: Public regenerative medicine company marketing FDA-approved skin substitutes (Apligraf, Dermagraft, PuraPly) for chronic wounds and burns. Most directly comparable peer given its focus on bioactive wound coverings derived from living cells and ECM.
• Kerecis: Develops and commercializes fish-skin-based ECM wound matrices (Kerecis Omega3 Wound) for burns and chronic wounds. Closely comparable as an animal-derived ECM biologic scaffold company competing in the same skin-substitute category.
• ACell: Develops and markets ECM-based wound care devices (Cytal, MicroMatrix) derived from porcine urinary bladder. Comparable as an animal-derived ECM scaffold company targeting wound healing and tissue repair with overlapping mechanism and indications.

Broad incumbents

• Integra LifeSciences: Large diversified medical device company with a major regenerative tissue technologies franchise (Integra Dermal Regeneration Template, AmnioExcel). Comparable as a broader incumbent in skin substitutes and wound regeneration with established hospital sales.
• Smith+Nephew: Global medical device company with a dedicated Advanced Wound Management division selling collagen-based dressings, skin substitutes, and regenerative wound-care products. Comparable as a broad incumbent with deep wound-care commercial infrastructure.
• MTF Biologics: Nonprofit tissue bank that develops and distributes allograft-based skin substitutes and wound-care biologics (e.g., AmnioBand, AlloPatch). Comparable as an established supplier of regenerative skin and wound-care products to hospitals and clinics.
• Convatec: Global medical products company with a significant advanced wound care portfolio (Avelle, Aquacel, InnovaMatrix). Comparable as a broad incumbent with established reimbursement and distribution in the wound-care category RegenX is targeting.

Emerging players

• Vericel: Commercial-stage cell therapy company selling MACI (cartilage repair) and Epicel (burns). Comparable as a regenerative medicine company with FDA-approved products in adjacent tissue regeneration indications (burns, soft tissue).
• PolarityTE: Regenerative medicine company developing autologous skin regeneration technology (SkinTE). Comparable as a smaller, similarly-staged regenerative skin/wound-healing company pursuing biologic pathway approvals.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/regenx-sceince

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RegenX Science